August 2013, Vol 6 ADA 2013 Highlights
Chicago, IL—On the 30th anniversary of the landmark Diabetes Control and Complications Trial (DCCT), the results of its 20-year observational Epidemiology of Diabetes Interventions and Complications (EDIC) study showed substantial reductions in the risk of developing severe eye disease, impaired kidney function, heart disease, and stroke with long-term intensive therapy in patients with type 1 diabetes. The results were presented at the 2013 American Diabetes Association annual meeting.
New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%
San Francisco, CA—Ranolazine extended release (Ranexa) reduces the frequency of anginal episodes in patients with type 2 diabetes, and its effects are more pronounced in patients with poorer glycemic control, according to new data released at the 2013 American College of Cardiology annual meeting.
Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes
Chicago, IL—A series of 8 phase 3 clinical trials that compared albiglutide, an investigational glucagon-like peptide (GLP)-1 receptor agonist, with 5 currently used treatment scenarios showed the drug effectively lowered hemoglobin (Hb) A1c, the primary outcome of the studies, in patients with uncontrolled type 2 diabetes. Albiglutide is administered once weekly, via an easy-to-use injection pen.
San Francisco, CA—The impact of obesity on patients with diabetes is well-established. Weight loss can significantly impact diabetes. In a recent study, obese patients who were offered modest financial incentives over an extended period of time as part of a weight-loss program were significantly more likely to maintain their weight loss than patients in an identical program without the financial incentives, according to Steven L. Driver, MD, MPH, Internal Medicine Resident, Department of Internal Medicine, Mayo Clinic, Rochester, MN, at the 2013 American College of Cardiology annual meeting.
Chicago, IL—Microvascular and macrovascular complications in type 2 diabetes were shown to be reduced with canagliflozin (Invokana) 100 mg and 300 mg compared with lifestyle measures alone, according to Cheryl A. Neslusan, PhD, Global Strategic Marketing and Market Access, Janssen Global Services, Raritan, NJ, and colleagues. They presented the results of their long-term economic model at the 2013 American Diabetes Association annual meeting.
Chicago, IL—The first US-based study to compare healthcare resource utilization and costs during the first 6 months after starting treatment with the dipeptidyl peptidase (DPP)-4 agent saxagliptin (Onglyza) or sitagliptin (Januvia) in patients with type 2 diabetes was reported at the 2013 American Diabetes Association annual meeting by Jasmina I. Ivanova, Vice President, Analysis Group, New York.
Chicago, IL—Diabetes foot infection comprised 2.5 million (3.8%) of the 66.1 million diabetes-related inpatient visits that occurred between 2001 and 2010 in the United States, according to data presented at the 2013 American Diabetes Association annual meeting.
Chicago, IL—A “team of 4” approach to achieve the “ABC goals”—hemoglobin (Hb) A1c %, blood pressure low-density lipoprotein cholesterol ular disease (CVD) risk provides significant cost-savings in managed care, according to an outcomes evaluation presented by Swarna S. Varma, MD, of Pittsburgh Endocrine and Diabetes Associates, Bridgeville, PA, at the 2013 American Diabetes Association annual meeting. The team care approach entails the involvement and accountability of the physician, staff, patient, and family.
San Francisco, CA—Reform to the healthcare system did not end with passage of the Affordable Care Act. The rise in healthcare costs may force capitated payments, integrated-care payment methods, and alternate forms of care delivery, according to presenters in a session on healthcare reform at the 2013 American College of Cardiology (ACC) meeting.
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Diabetes affects an estimated 25.8 million people in the United States—a staggering 8.3% of the population. Type 2 diabetes accounts for 90% to 95% of all adult cases of diabetes. In addition, an estimated 35% of US adults aged ≥20 years have prediabetes, and the prevalence of prediabetes jumps to 50% in adults aged ≥65 years.
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19